Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia

Publication Date: March 1, 2004

The adoption of Gleevec, a pioneering drug in the treatment of CML, highlights challenges and opportunities in bringing drugs treating rare diseases to market.